Table 1.
Demographic data for all participants and the subgroup of dementia and MCI with amyloid pathology (CSF Aβ42 < 500 pg/ml) and controls without amyloid pathology (CSF Aβ42 > 500 pg/ml)
| All cases | Amyloid subgroups | |||||
| Dementia | MCI | Controls | Dementia Aβ42 + | MCI Aβ42 + | Controls Aβ42 – | |
| Cases | 359 (72%) | 96 (19%) | 43 (9%) | 214 (71%) | 51 (17%) | 36 (12%) |
| Age, y | 72.8 (7.7) | 70.3 (9.2) | 58.5 (10.9) | 72.0 (8.0) | 71.1 (8.8) | 56.6 (9.9) |
| Sex, female/male | 241/118 (67/33%) | 39/57 (41/59%) | 18/25 (42/58%) | 137/76 (64/36%) | 25/26 (49/51%) | 14/22 (39/61%) |
| MMSE score | 19.3 (4.7) | 24.3 (2.8) | 26.3 (4.8) | 19.1 (4.5) | 24.1 (2.6) | 26.9 (3.7) |
| APOE ɛ4 prevalence | 241 (72%) | 48 (67%) | 7 (23%) | 161 (80%) | 31 (73%) | 5 (19%) |
| CSF markers, pg/ml | ||||||
| Aβ42 | 502 (179) | 530 (248) | 767 (266) | 391 (71) | 346 (88) | 836 (220) |
| tTau | 507 (290) | 417 (225) | 223 (111) | 526 (289) | 435 (224) | 211 (93) |
| pTau | 77 (34) | 71 (29) | 51 (19) | 79 (34) | 73 (29) | 52 (19) |
Aβ42, amyloid-β 42; APOE ɛ4, Apolipoprotein E epsilon 4; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; pTau, phosphorylated tau; tTau, total tau. Values are displayed as means (standard deviation) or number (percentage). Missing values: 1 for tTau, 68 for MMSE and 59 for APOE.